GlassScriptPhysician profile
Ibrahim M Saeed
NPI 1164639670
$22,988.25
in general payments reported to CMS, 2019-2025
29 companies · $2,875 in 2025
The $2,875 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $17K · 2021: $52.36 · 2022: $1,606 · 2023: $616 · 2024: $768 · 2025: $2,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,549 · Consulting Fee: $1,710.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.76 |
| Consulting Fee | $1,710.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $13,500.00 | 2020 | |
| Pfizer INC. | $3,669.20 | 2019-2025 | |
| Ge Healthcare | $1,973.12 | 2020-2025 | |
| Bridgebio Pharma, INC. | $1,880.73 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $286.20 | 2023-2025 | Onpattro, Amvuttra |
| Akcea Therapeutics, INC. | $189.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $178.45 | 2022-2025 | |
| Heartflow, INC. | $159.21 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $132.08 | 2022-2025 | Verquvo, Lagevrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.17 | 2023-2025 | Jardiance |
| Abbott Laboratories | $98.86 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $91.96 | 2022-2025 | Camzyos |
| Scpharmaceuticals INC. | $89.79 | 2023-2025 | |
| Novo Nordisk INC | $86.02 | 2023-2024 | Ozempic, Rybelsus |
| Amgen INC. | $77.66 | 2023-2025 | Repatha, Repatha |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Canon Medical Systems USA, INC. | $67.51 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $54.82 | 2024-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $52.14 | 2024 | Xarelto |
| Boston Scientific Corporation | $45.74 | 2022-2024 | Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $44.04 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $33.95 | 2023 | Arcalyst |
| Cleerly, INC. | $25.97 | 2025 | Cleerly Labs, Cleerly Ischemia |
| United Imaging Healthcare North America LLC | $25.95 | 2021 | |
| Esperion Therapeutics, INC. | $25.64 | 2025 | Nexletol |
| Vital Connect, INC | $23.17 | 2023 | Vitalpatch Rtm |
| Recor Medical INC | $20.40 | 2025 | Paradise Ultrasound Renal Denervation System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.00 | 2022 | |
| Cvrx, INC. | $17.20 | 2025 | Barostim Neo System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Saeed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.